Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shannen Allen

Ophthalmology Rockville, MD Medical Doctor

NPI 1407876360 CMS profile 602320

15005 Shady Grove Rd., Ste 100, Rockville, MD 20850

Open in the dashboard

General payments

$4,636

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shannen Allen of Rockville, MD is reported in the CMS Open Payments database as having received $4,636 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $870 34
2024 General $1,364 48
2023 General $830 33
2022 General $456 26
2021 General $539 33
2020 General $286 20
2019 General $291 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shannen Allen
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Shannen Allen were reported at $870. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Shannen Allen Ophthalmology median Middle half National median
2019 $291 $258 $104–$655 $163
2020 $286 $126 $45–$321 $114
2021 $539 $205 $76–$534 $132
2022 $456 $266 $100–$678 $149
2023 $830 $308 $117–$745 $160
2024 $1,364 $340 $127–$846 $164
2025 $870 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mallinckrodt Hospital Products Inc. $844 21 payments
  2. Sun Pharmaceutical Industries Inc. $537 27 payments
  3. Tarsus Pharmaceuticals, Inc. $467 16 payments
  4. Alcon Vision LLC $464 21 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $340 25 payments
  6. Bausch & Lomb Americas Inc. $335 16 payments
  7. Novartis Pharmaceuticals Corporation $320 22 payments
  8. Allergan Inc. $246 14 payments
  9. Johnson & Johnson Vision Care, Inc. $244 13 payments
  10. Oyster Point Pharma, Inc. $192 8 payments
  11. Other $646 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,518 208 payments
  2. Education $118 2 payments
Products named General payments · program years 2019–2025
  1. ACTHAR $844 21 payments
  2. Cequa $524 26 payments
  3. XDEMVY $467 16 payments
  4. XIIDRA $319 22 payments
  5. VYZULTA $251 16 payments
  6. Acuvue $210 11 payments
  7. MIEBO $171 8 payments
  8. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $138 4 payments
  9. RXSIGHT CONTACT LENS $138 4 payments
  10. RXSIGHT INJECTOR CARTRIDGE $138 4 payments
  11. Other $2,533 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

524

Median for Ophthalmology: 891

Drug cost

$102,364

Median for Ophthalmology: $68,233

Branded share of claims

48.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 21 $35,555
Lumigan Bimatoprost Brand 28 $19,916
Miebo Perfluorohexyloctane/Pf Brand 17 $19,790
Travoprost Generic 16 $4,569
Loteprednol Etabonate Generic 22 $4,182
Combigan Brimonidine Tartrate/Timolol Brand 11 $3,791
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 116 $3,575
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 36 $3,307
Latanoprost Generic 188 $2,862
Timolol Maleate Generic 20 $2,655

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$123,683

Medicare's payments for the services billed

Medicare patients

815

Average age 74

Services billed

1,835

529 women, 286 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 40%
Diabetes 28%
Ischemic heart disease 22%
Osteoporosis 21%
Cancer 16%
Depression 15%
Chronic kidney disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ACTHAR
  • Mallinckrodt Hospital Products Inc. $545
$545 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $237
$237 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $89
$89 — —
MIEBO
  • Bausch & Lomb Americas Inc. $72
$72 17 —
TYRVAYA
  • Oyster Point Pharma, Inc. $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record